# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-03-10T17:08:13.086317
**Route:** Direct Google API + PDF
**Paper Hash:** 3ca8f29a17ce66ee
**Tokens:** 21438 in / 654 out
**Response SHA256:** 3478a27bf65ffdaa

---

I have reviewed the draft paper for fatal errors across the four required categories.

**ADVISOR VERDICT: PASS**

My review did not identify any fatal errors that would preclude submission to a journal. Here is a summary of the checks performed:

1.  **Data-Design Alignment:**
    *   **Treatment Timing:** The paper exploits the 2022 Russian gas shock. The Eurostat mortality data used covers 2015–2024 (Table 1 and Section 4.1), which correctly encompasses the pre-treatment period and multiple post-treatment winter cohorts (2022/23, 2023/24, and part of 2024/25).
    *   **Post-treatment observations:** The DiD design has clear post-treatment observations for the treatment cohorts as evidenced in Figure 2 and Figure 7.
    *   **Consistency:** The definition of Russian gas dependence (2021 share) is consistent across Table 1 and the regression specifications.

2.  **Regression Sanity:**
    *   **Standard Errors:** Standard errors in Table 2 and Table 3 are within reasonable bounds for the mortality outcomes (e.g., SE of 0.567 for a mean of ~21). No instances of SE > 1000 or SE > 100 × |coefficient|.
    *   **Coefficients:** Coefficients for log outcomes (Table 2, Col 3) are small (-0.025), well below the "fatal" threshold of 10.
    *   **Impossible Values:** R² is not explicitly reported in the summary tables but there are no negative values, "NA", "NaN", or "Inf" results in the reported regression outputs.

3.  **Completeness:**
    *   **Placeholders:** Scanned the document for "TBD", "PLACEHOLDER", "XXX", and "Sun-Abraham". None were found.
    *   **Required Elements:** Sample sizes (N) are clearly reported in all regression tables (Tables 2, 3, 4, 5). Standard errors are provided in parentheses for all estimates.
    *   **Analyses:** Results for all major claims (Age-gradient, Placebos, Heterogeneity) described in the text are present in Tables 3, 4, and 5.

4.  **Internal Consistency:**
    *   **Number Matching:** Statistics cited in the abstract (e.g., coefficient of 0.46, p=0.27) match the preferred specification in Table 2, Column 5.
    *   **Timing:** The "Post" definition (ISO weeks 40-13, 2022-2024) is consistent across the text and table notes.
    *   **Sample Periods:** Changes in sample sizes across columns in Table 2 are explicitly explained in the notes (e.g., dropping COVID years, missing HDD data).

**ADVISOR VERDICT: PASS**